Premium
Systemic chemotherapy and sequential locoregional radiotherapy in initially metastatic nasopharyngeal carcinoma: Retrospective analysis with 821 cases
Author(s) -
Huang Tianying,
Su Ning,
Zhang Xuanye,
Ma Shuyun,
Zhong Guangzheng,
Tian Xiaopeng,
Chen Qiuyan,
Tang Linglong,
Lu Lixia,
Fang Yu,
Cai Jun,
Cai Qingqing
Publication year - 2020
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26130
Subject(s) - medicine , nasopharyngeal carcinoma , chemotherapy , regimen , radiation therapy , oncology , paclitaxel , retrospective cohort study
Background We designed this retrospective study to explore the best treatment modality for patients with initially metastatic nasopharyngeal carcinoma (NPC). Methods From 2008 to 2017, 821 patients were enrolled. Treatment modalities and prognostic factors were analyzed. Results Compared with chemotherapy alone and radiotherapy‐based treatment, systemic chemotherapy‐sequential locoregional radiotherapy to the nasopharyngeal primary tumor site were associated with a significantly increased 3‐year overall survival (OS) rate (40.3%, 11.7%, and 22.9%, P < .001). The overall response rate of the paclitaxel combined with platinum and fluorouracil (TPF) regimen as first‐line chemotherapy was higher than that of the paclitaxel plus platinum (TP) regimen (78.2% vs 70.0%, P = .038). A better OS was achieved in the TPF group compared to doublet drug regimens (3‐year OS, 35.7% vs 25.3%, P < .001). Conclusions Systemic chemotherapy‐sequential locoregional radiotherapy may prolong OS and progression‐free survival for selected patients with initially metastatic NPC.